ARTICLE | Clinical News
Heplisav regulatory update
February 24, 2014 8:00 AM UTC
Dynavax withdrew an MAA from EMA for Heplisav, its adjuvanted HBV vaccine. According to the company, EMA said Heplisav's safety database is too small to rule out a risk of less common serious adverse...